相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Sequence Variants in SLC6A3, DRD2, and BDNF Genes and Time to Levodopa-Induced Dyskinesias in Parkinson's Disease
Natalie Kaplan et al.
JOURNAL OF MOLECULAR NEUROSCIENCE (2014)
Dopa-decarboxylase gene polymorphisms affect the motor response to L-dopa in Parkinson's disease
David Devos et al.
PARKINSONISM & RELATED DISORDERS (2014)
Association of common genetic variants of HOMER1 gene with levodopa adverse effects in Parkinson's disease patients
A. F. Schumacher-Schuh et al.
PHARMACOGENOMICS JOURNAL (2014)
Dopamine-Angiotensin Interactions in the Basal Ganglia and Their Relevance for Parkinson's Disease
Jose L. Labandeira-Garcia et al.
MOVEMENT DISORDERS (2013)
The Genetics of Parkinson's Disease: Progress and Therapeutic Implications
Andrew B. Singleton et al.
MOVEMENT DISORDERS (2013)
Association of UDP-glucuronosyltransferase 1A9 polymorphisms with adverse reactions to catechol-O-methyltransferase inhibitors in Parkinson's disease patients
Marco Ferrari et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2012)
Catechol-O-methyltransferase Val158Met and the Risk of Dyskinesias in Parkinson's Disease
Lonneke M. L. de lau et al.
MOVEMENT DISORDERS (2012)
Genetic variant of HTR2A associates with risk of impulse control and repetitive behaviors in Parkinson's disease
Jee-Young Lee et al.
PARKINSONISM & RELATED DISORDERS (2012)
Role of genetic polymorphisms of the dopaminergic system in Parkinson's disease patients with impulse control disorders
Annamaria Vallelunga et al.
PARKINSONISM & RELATED DISORDERS (2012)
Dyskinesias in patients with Parkinson's disease: Effect of the leucine-rich repeat kinase 2 (LRRK2) G2019S mutation
Gilad Yahalom et al.
PARKINSONISM & RELATED DISORDERS (2012)
DRD2 haplotype is associated with dyskinesia induced by levodopa therapy in Parkinson's disease patients
Mariana Rieck et al.
PHARMACOGENOMICS (2012)
NMDA receptor genotypes associated with the vulnerability to develop dyskinesia
S. A. Ivanova et al.
TRANSLATIONAL PSYCHIATRY (2012)
The role of apolipoprotein E polymorphisms in levodopa-induced dyskinesia
I. Molchadski et al.
ACTA NEUROLOGICA SCANDINAVICA (2011)
The COMT Val158Met Polymorphism Affects the Response to Entacapone in Parkinson's Disease: A Randomized Crossover Clinical Trial
Jean-Christophe Corvol et al.
ANNALS OF NEUROLOGY (2011)
Differential Genetic Susceptibility in Diphasic and Peak-Dose Dyskinesias in Parkinson's Disease
Jee-Young Lee et al.
MOVEMENT DISORDERS (2011)
Racial Differences May Influence the Role of Cholecystokinin Polymorphisms in Parkinson's Disease Hallucinations
Jennifer G. Goldman et al.
MOVEMENT DISORDERS (2011)
OCT1 polymorphism is associated with response and survival time in anti-Parkinsonian drug users
Matthijs L. Becker et al.
NEUROGENETICS (2011)
Genotype and Ancestry Modulate Brain's DAT Availability in Healthy Humans
Elena Shumay et al.
PLOS ONE (2011)
Maladaptive Plasticity of Serotonin Axon Terminals in Levodopa-Induced Dyskinesia
Daniella Rylander et al.
ANNALS OF NEUROLOGY (2010)
The ANKK1 Gene Associated with Addictions Is Expressed in Astroglial Cells and Upregulated by Apomorphine
Janet Hoenicka et al.
BIOLOGICAL PSYCHIATRY (2010)
Maladaptive striatal plasticity in L-DOPA-induced dyskinesia
M. Angela Cenci et al.
RECENT ADVANCES IN PARKINSONS DISEASE: BASIC RESEARCH (2010)
Clinical and pharmacogenetic determinants for the discontinuation of non-ergoline dopamine agonists in Parkinson's disease
Maurits E. L. Arbouw et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Association of the DRD2 and DRD3 polymorphisms with response to pramipexole in Parkinson's disease patients
Ying-Zi Liu et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2009)
BDNF val66met influences time to onset of levodopa induced dyskinesia in Parkinson's disease
T. Foltynie et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2009)
Striatal Dopamine Transporter Availability Associated with Polymorphisms in the Dopamine Transporter Gene SLC6A3
Elisabeth M. van de Giessen et al.
JOURNAL OF NUCLEAR MEDICINE (2009)
Genetic polymorphism of Angiotensin-Converting Enzyme is not associated with the development of Parkinson's disease and of L-dopa-induced adverse effects
Esterina Pascale et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2009)
Motor Complications in Patients Form the German Competence Network on Parkinson's Disease and the DRD3 Ser9Gly Polymorphism
Sebastian Paus et al.
MOVEMENT DISORDERS (2009)
HOMER1 Promoter Analysis in Parkinson's Disease: Association Study with Psychotic Symptoms
Vincenzo De Luca et al.
NEUROPSYCHOBIOLOGY (2009)
Levodopa-related motor complications - Phenomenology
Susan H. Fox et al.
MOVEMENT DISORDERS (2008)
The DRD2 TaqIA polymorphism and demand of dopaminergic medication in Parkinson's disease
Sebastian Paus et al.
MOVEMENT DISORDERS (2008)
Scales to assess psychosis in Parkinson's disease:: Critique and recommendations
Hubert H. Fernandez et al.
MOVEMENT DISORDERS (2008)
The Unified Dyskinesia Rating Scale: Presentation and Clinimetric Profile
Christopher G. Goetz et al.
MOVEMENT DISORDERS (2008)
Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Scale Presentation and Clinimetric Testing Results
Christopher G. Goetz et al.
MOVEMENT DISORDERS (2008)
The association of functional catechol-O-methyltransferase haplotypes with risk of Parkinson's disease, levodopa treatment response, and complications
Monika Bialecka et al.
PHARMACOGENETICS AND GENOMICS (2008)
Polyspecific organic cation transporters: Structure, function, physiological roles, and biopharmaceutical implications
Hermann Koepsell et al.
PHARMACEUTICAL RESEARCH (2007)
Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in Parkinsonian rats
Manolo Carta et al.
BRAIN (2007)
Identification and characterization of two nuclear factor-κB sites in the regulatory region of the dopamine D2 receptor
Sandra Bontempi et al.
ENDOCRINOLOGY (2007)
Genetic polymorphism of the angiotensin converting enzyme and L-dopa-induced adverse effects in Parkinson's disease
Juei-Jueng Lin et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2007)
Genotype and smoking history affect risk of levodopa-induced dyskinesias in Parkinson's disease
Judith A. Strong et al.
MOVEMENT DISORDERS (2006)
Apolipoprotein e and dementia in Parkinson disease -: A meta-analysis
XM Huang et al.
ARCHIVES OF NEUROLOGY (2006)
Apolipoprotein epsilon 4 advances appearance of psychosis in patients with Parkinson's disease
B Feldman et al.
ACTA NEUROLOGICA SCANDINAVICA (2006)
Epidemiology of Parkinson's disease
Lonneke M. L. de Lau et al.
LANCET NEUROLOGY (2006)
Apolipoprotein E ε4 and catechol-O-methyltransferase alleles in autopsy-proven Parkinson's disease:: Relationship to dementia and hallucinations
R Camicioli et al.
MOVEMENT DISORDERS (2005)
Preprohypocretin polymorphisms in Parkinson disease patients reporting Sleep attacks
I Rissling et al.
SLEEP (2005)
Genetic polymorphism of catechol-O-methyltransferase and levodopa pharmacokinetic -: Pharmacodynarnic pattern in patients with Parkinson's disease
M Contin et al.
MOVEMENT DISORDERS (2005)
Sex differences in clinical and genetic determinants of levodopa peak-dose dyskinesias in Parkinson disease -: An exploratory study
M Zappia et al.
ARCHIVES OF NEUROLOGY (2005)
Dopamine transporter gene polymorphism, SPECT imaging, and levodopa response in patients with Parkinson disease
M Contin et al.
CLINICAL NEUROPHARMACOLOGY (2004)
Genetic polymorphisms subjects in Parkinson disease subjects with or without hallucinations - An analysis of the cholecystokinin system
JG Goldman et al.
ARCHIVES OF NEUROLOGY (2004)
Association of daytime sleepiness with COMT polymorphism in patients with Parkinson disease:: a pilot study
B Frauscher et al.
SLEEP (2004)
Dopamine receptor gene polymorphisms in Parkinson's disease patients reporting sleep attacks
I Rissling et al.
MOVEMENT DISORDERS (2004)
Association study of dopamine D2, D3, D4 receptor and serotonin transporter gene polymorphisms with sleep attacks in Parkinson's disease
S Paus et al.
MOVEMENT DISORDERS (2004)
Identification and characterization of ANKK1: A novel kinase gene closely linked to DRD2 on chromosome band 11q23.1
MJ Neville et al.
HUMAN MUTATION (2004)
The effect of monoamine oxidase B (MAOB) and catechol-O-methyltransferase (COMT) polymorphisms on levodopa therapy in patients with sporadic Parkinson's disease
M Bialecka et al.
ACTA NEUROLOGICA SCANDINAVICA (2004)
L-Dopa-induced adverse effects in PD and dopamine transporter gene polymorphism
R Kaiser et al.
NEUROLOGY (2003)
Cholecystokinin, cholecystokinin-A receptor and cholecystokinin-B receptor gene polymorphisms in Parkinson's disease
J Wang et al.
PHARMACOGENETICS (2003)
Staging of brain pathology related to sporadic Parkinson's disease
H Braak et al.
NEUROBIOLOGY OF AGING (2003)
Association between catechol-O-methyltransferase gene polymorphisms and wearing-off and dyskinesia in Parkinson's disease
M Watanabe et al.
NEUROPSYCHOBIOLOGY (2003)
Cholecystokinin modulation of mesolimbic dopamine function: Regulation of motivated behaviour
S Rotzinger et al.
PHARMACOLOGY & TOXICOLOGY (2002)
COMT genotype and effectiveness of entacapone in patients with fluctuating Parkinson's disease
MS Lee et al.
NEUROLOGY (2002)
Dopamine D5 receptor gene polymorphism and the risk of levodopa-induced motor fluctuations in patients with Parkinson's disease
J Wang et al.
NEUROSCIENCE LETTERS (2001)
Association study of dopamine D2, D3 receptor gene polymorphisms with motor fluctuations in PD
J Wang et al.
NEUROLOGY (2001)
Genotypes of catechol-O-methyltransferase and response to levodopa treatment in patients with Parkinson's disease
MS Lee et al.
NEUROSCIENCE LETTERS (2001)
Genetic variation analysis in Parkinson disease patients with and without hallucinations - Case-control study
CG Goetz et al.
ARCHIVES OF NEUROLOGY (2001)
The human dopamine transporter gene:: the 5′-flanking region reveals five diallelic polymorphic sites in a Caucasian population sample
C Rubie et al.
NEUROSCIENCE LETTERS (2001)
The relationship between COMT genotype and the clinical effectiveness of tolcapone, a COMT inhibitor, in patients with Parkinson's disease
DJ Chong et al.
CLINICAL NEUROPHARMACOLOGY (2000)
Association study of dopamine receptor gene polymorphisms with drug-induced hallucinations in patients with idiopathic Parkinson's disease
AJ Makoff et al.
PHARMACOGENETICS (2000)
分享论文
